Key partners

National Institutes of Health

The National Institutes of Health (NIH) is the government agency that administers federal funding for medical research across the country and around the world. Within the NIH, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is the lead institute for coordinating and conducting research to cure, prevent, and treat T1D and its complications. In addition to administering the Special Diabetes Program (SDP) funds, NIDDK (and other institutes within the NIH) awards grants on a competitive basis with funding the NIH receives from Congress annually through the annual appropriations process. 

Food and Drug Administration

The U.S. Food and Drug Administration (FDA) is tasked with assuring the safety and efficacy of drugs, biologics, and medical devices, including insulin, artificial pancreas technology, and other new diabetes therapies. Breakthrough T1D and the T1D community have a vested interest in the actions of the FDA and its funding levels as new treatments will require FDA review and approval before becoming available. 

Key to progress

Valued partners

The NIH and FDA play a vital role in bringing life-changing therapies to market, and they must be funded at the highest possible level. Breakthrough T1D participates in several broad coalitions to secure robust support for these entities. 


The NIH is funded currently at $47.7 billion for Fiscal Year 2023 (FY23). The FDA is funded currently at $8.4 billion. 

Special Diabetes Program

The Special Diabetes Program (SDP) is a critical program that provides $160 million annually for T1D research at the National Institutes of Health. The SDP complements Breakthrough T1D’s research efforts. Together, they are leading to new insights and therapies that are improving the lives of people with diabetes and accelerating progress to cures.